Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

GLP 1s & Sarcopenia: Fact vs Hype

Dr Deb Mills

Dr Deb Mills

The New Dengue Vaccine – What You Need to Know

Dr Robert Hungerford

Dr Robert Hungerford

Hypertriglyceridaemia – Causes, Assessment & Management of CV Risk

A/Prof Michelle Rodrigues

A/Prof Michelle Rodrigues

Management of Photoageing

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

A/Prof Martin MacDonald

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023